EGRX Eagle Pharmaceuticals Inc.

64.78
-0.07  -0%
Previous Close 64.85
Open 64.70
Price To book 5.65
Market Cap 966622738
Shares 14,921,623
Volume 196,416
Short Ratio 14.35
Av. Daily Volume 225,651

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial initiation announced December 7, 2017. Trial completion and NDA filing due 4Q 2018.
Fulvestrant
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018
  2. Eagle Pharmaceuticals, Inc. to Present at 2018 RBC Capital Markets Global Healthcare Conference
  3. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX
  4. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  5. Eagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare Conference
  6. ETFs with exposure to Eagle Pharmaceuticals, Inc. : December 28, 2017
  7. Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
  8. Research Report Identifies 2U, AK Steel Holding, American Water Works, Urban Edge Properties, Guidewire Software, and Eagle Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  9. Cramer's lightning round: Buy Cisco when it goes below $3...
  10. Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
  11. Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference
  12. Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
  13. Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017
  14. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017
  15. Eagle Pharmaceuticals posts 3Q profit
  16. Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results